Commercialization aimed at eradicating genetic diseases and creating a disease-free future
First written in FY2017. 10 of 28 entries say "Restated". Latest entry: 2026-08-07.
No other company in this theme has enough history to compare yet.
- 2026-08-07AdvancedEarnings presentation
「The importance of genetic testing was also demonstrated for identifying and managing hereditary disease risks and improving animal welfare.」
Research findings linking the identification and management of hereditary disease risks with animal welfare were presented as evidence of the importance of genetic testing. - FY2026AdvancedAnnual report
「We sell genetic testing to pet shops and breeders to help avoid hereditary diseases when pets are born, through genetic testing of parent and offspring. We also sell an intestinal flora measurement service for animal health checks (どうぶつ健活), among other products and services. However, due mainly to stable orders for genetic testing specimens, ordinary revenue for the consolidated fiscal year was ¥335 million, up 4.6% from the previous consolidated fiscal year.」
Sales of parent-offspring genetic testing and どうぶつ健活 continued, and related business revenue was ¥335 million, up 4.6% from the previous fiscal year, due mainly to stable specimen orders. - FY2026-H1Related business revenue increased despite lower specimen ordersAnnual report
「We sell genetic testing to pet shops and breeders to help avoid hereditary diseases when pets are born, through genetic testing of parent and offspring. We also sell an intestinal flora measurement service for animal health checks (どうぶつ健活), among other products and services. However, due mainly to a decline in orders for genetic testing specimens, ordinary revenue for the six-month interim consolidated accounting period was ¥167 million, up 3.9% year on year.」
While the decline in orders for genetic testing specimens was noted, ordinary revenue from the genetic testing and related businesses was ¥167 million, up 3.9% year on year. - FY2025Specimen volume declined while technology capabilities expandedAnnual report
「The number of genetic testing specimens reached approximately 66,000 in fiscal 2024. The company also expanded the business by advancing the development of technology capable of measuring personality (behavior), breed, coat color, physical constitution and parentage in a single test.」
The number of genetic testing specimens was approximately 66,000, while the company advanced technology development to measure personality, breed, coat color, physical constitution and parentage in a single test. - FY2025-H1Related business revenue flat, specimen orders declinedAnnual report
「We sell genetic testing to pet shops and breeders to help avoid hereditary diseases when pets are born, through genetic testing of parent and offspring. We also sell an intestinal flora measurement service for animal health checks (どうぶつ健活), among other products and services. However, due mainly to a decline in orders for genetic testing specimens, ordinary revenue for the six-month interim consolidated accounting period was ¥161 million, down 0.2% year on year.」
Sales of parent-offspring genetic testing and どうぶつ健活 continued, but due mainly to a decline in specimen orders, ordinary revenue from the genetic testing and related businesses was ¥161 million, down 0.2% year on year. - FY2024-Q3Continued decline in revenue from related businessesAnnual report
「At アニコム パフェ株式会社, we sell genetic testing to pet shops and breeders to help avoid hereditary diseases when pets are born, through genetic testing of parent and offspring. We also sell an intestinal flora measurement service for animal health checks (どうぶつ健活), among other products and services. Ordinary revenue for the nine-month period ended the third quarter was ¥245 million, down 22.5% year on year.」
Sales of parent-offspring genetic testing and どうぶつ健活 continued, but ordinary revenue from the genetic testing and related businesses was ¥245 million, down 22.5% year on year. - FY2024-Q2Continued decline in revenue from related businessesAnnual report
「At アニコム パフェ株式会社, we sell genetic testing to pet shops and breeders to help avoid hereditary diseases when pets are born, through genetic testing of parent and offspring. We also sell an intestinal flora measurement service for animal health checks (どうぶつ健活), among other products and services. Ordinary revenue for the six-month period ended the second quarter was ¥161 million, down 26.7% year on year.」
Sales of parent-offspring genetic testing and どうぶつ健活 continued, but ordinary revenue from the genetic testing and related businesses was ¥161 million, down 26.7% year on year. - FY2024-Q1Continued decline in revenue from related businessesAnnual report
「At アニコム パフェ株式会社, we sell genetic testing to pet shops and breeders to help avoid hereditary diseases when pets are born, through genetic testing of parent and offspring. We also sell an intestinal flora measurement service for animal health checks (どうぶつ健活), among other products and services. Ordinary revenue for the three-month period ended the first quarter was ¥82 million, down 25.3% year on year.」
Sales of parent-offspring genetic testing and どうぶつ健活 continued, but ordinary revenue from the genetic testing and related businesses was ¥82 million, down 25.3% year on year. - FY2023Specimen volume expanded while related revenue declinedAnnual report
「In the genetic testing business operated by アニコム パフェ株式会社, the number of genetic testing specimens reached approximately 92,000 in fiscal 2022. The company also expanded the business by advancing the development of technology capable of measuring personality (behavior), breed, coat color, physical constitution and parentage in a single test.」
The number of genetic testing specimens reached approximately 92,000 in fiscal 2022, while technology development to expand the scope of measurement also progressed. Meanwhile, ordinary revenue from the genetic testing and related businesses was ¥405 million, down 32.0% from the previous fiscal year. - FY2023-Q3Continued decline in revenue from related businessesAnnual report
「At アニコム パフェ株式会社, we sell genetic testing to pet shops and breeders to help avoid hereditary diseases when pets are born, through genetic testing of parent and offspring. We also sell an intestinal flora measurement service for animal health checks (どうぶつ健活), among other products and services. Ordinary revenue for the nine-month period ended the third quarter was ¥316 million, down 27.7% year on year.」
Sales of parent-offspring genetic testing and どうぶつ健活 continued, but ordinary revenue from the genetic testing and related businesses was ¥316 million, down 27.7% year on year. - FY2023-Q2Continued decline in revenue from related businessesAnnual report
「アニコム パフェ株式会社 sells genetic tests to pet shops and breeders to help avoid genetic diseases when pets are born through genetic testing of parents and offspring. It also sells intestinal flora measurement services, including “どうぶつ健活,” aimed at checking animals’ health. Ordinary revenue for the six-month cumulative period of the second quarter was ¥220 million, down 25.1% year on year.」
Although sales of genetic tests for parents and offspring and どうぶつ健活 continued, ordinary revenue from the genetic testing and related businesses was ¥220 million, down 25.1% year on year. - FY2023-Q1Decline in revenue from related businessesAnnual report
「アニコム パフェ株式会社 sells genetic tests to pet shops and breeders to help avoid genetic diseases when pets are born through genetic testing of parents and offspring. It also sells intestinal flora measurement services, including “どうぶつ健活,” aimed at checking animals’ health. Ordinary revenue for the three-month cumulative period of the first quarter was ¥109 million, down 27.5% year on year.」
Although sales of genetic tests for parents and offspring and どうぶつ健活 continued, ordinary revenue from the genetic testing and related businesses was ¥109 million, down 27.5% year on year. - FY2022-Q3AdvancedAnnual report
「アニコム パフェ株式会社 sells genetic tests to pet shops and breeders to help avoid genetic diseases when pets are born through genetic testing of parents and offspring. It also sells intestinal flora measurement services, including “どうぶつ健活,” aimed at checking animals’ health. Ordinary revenue for the nine-month cumulative period of the third quarter was ¥438 million, up 17.6% year on year.」
Sales of genetic tests for parents and offspring and どうぶつ健活 continued, and ordinary revenue from the genetic testing and related businesses was ¥438 million, up 17.6% year on year. - FY2022-Q2AdvancedAnnual report
「アニコム パフェ株式会社 sells genetic tests to pet shops and breeders to help avoid genetic diseases when pets are born through genetic testing of parents and offspring. It also sells intestinal flora measurement services, including “どうぶつ健活,” aimed at checking animals’ health. Ordinary revenue for the nine-month cumulative period of the second quarter was ¥294 million, up 19.7% year on year.」
Sales of genetic tests for parents and offspring and “どうぶつ健活” continued, and ordinary revenue from the genetic testing and related businesses was ¥294 million, up 19.7% year on year. - FY2022-Q1RestatedAnnual report
「Regarding the genetic testing business, the company will use genetic testing of parents and offspring to avoid genetic diseases and connect this to breeding support that combines science, technology, and data, including genetic analysis, with medical support.」
The company continues to pursue a policy of avoiding genetic diseases through genetic testing of parents and offspring and providing breeding support combining genetic analysis and medical care. - FY2021AdvancedAnnual report
「As a result of these efforts, the company confirmed an overall downward trend in the proportion of affected animals with degenerative myelopathy (DM), a genetic disease known to affect breeds such as the Pembroke Welsh Corgi and German Shepherd Dog.」
As a result of genetic testing and breeding support since 2018, the company confirmed an overall decline in the proportion of animals affected by DM. - FY2021-Q3RestatedAnnual report
「Regarding the genetic testing business, the company will use genetic testing before and after breeding to avoid preventable genetic diseases, then connect this to breeding support that combines science, technology, and data, including genetic analysis, with medical support.」
The company continues to pursue a policy of avoiding genetic diseases through genetic testing before and after breeding and providing breeding support combining genetic analysis and medical care. - FY2021-Q2RestatedAnnual report
「Regarding the genetic testing business, the company will use genetic testing before and after breeding to avoid preventable genetic diseases, then connect this to breeding support that combines science, technology, and data, including genetic analysis, with medical support.」
The company continues to pursue a policy of avoiding genetic diseases through genetic testing before and after breeding and providing breeding support combining genetic analysis and medical care. - FY2021-Q1RestatedAnnual report
「Regarding the genetic testing business, the company will use genetic testing before and after breeding to avoid preventable genetic diseases, then connect this to breeding support that combines science, technology, and data, including genetic analysis, with medical support.」
The company continues to pursue a policy of avoiding genetic diseases through genetic testing before and after breeding and providing breeding support combining genetic analysis and medical care. - FY2020-Q3RestatedAnnual report
「Regarding the genetic testing business, the company will use genetic testing before and after breeding to avoid preventable genetic diseases, then connect this to breeding support that combines science, technology, and data, including genetic analysis, with medical support.」
The company continues to pursue a policy of avoiding genetic diseases through genetic testing and providing breeding support combining genetic analysis and medical care. - FY2019RaisedAnnual report
「Specifically, the Anicom Group has launched a genetic testing business aimed at eliminating hereditary diseases in animals, conducting genetic tests at its laboratory on pets sold through major pet shops, breeders, and other channels. By providing comprehensive support for breeding sites, including scientific knowledge and medical care based on data accumulated through these genetic tests, the Group aims to resolve various issues in breeding, thereby promote the distribution of healthy pets and ease, even slightly, owners’ concerns about pet illnesses and injuries, leading to an increase in the number of pets kept. Through this breeding support, the Group will also pursue measures to improve breeders’ revenue opportunities and stem the decline in the number of breeders. In addition, to address situations in which owners can no longer keep their pets because of illness or old age, or because their pets have become elderly and require care, the Group aims to create an environment in which owners can keep pets with peace of mind by operating senior-dog homes, lifelong-care facilities, shelters, and similar facilities that care for pets on owners’ behalf, thereby contributing to an increase in the number of pets kept.」
The scope of initiatives has expanded beyond launching genetic testing and conducting tests at the Group’s laboratory to include breeding support using test data, improving breeders’ revenue opportunities, and senior-dog homes and lifelong-care facilities. - FY2019-Q3RestatedAnnual report
「In particular, to eliminate genetic diseases, the company is providing breeding support that combines science, technology, and data, including genetic analysis, with medical support, while commercializing intestinal flora testing to promote animal health checks, food development using symbiotic bacteria as a key, lifestyle consulting, and other businesses.」
The company continues to commercialize breeding support combining genetic analysis and medical care, intestinal flora testing, and product development and consulting using symbiotic bacteria. - FY2019-Q2RestatedAnnual report
「In particular, to eliminate genetic diseases, the company is providing breeding support that combines science, technology, and data, including genetic analysis, with medical support, while commercializing intestinal flora testing to promote animal health checks, food development using symbiotic bacteria as a key, lifestyle consulting, and other businesses.」
The company continues to commercialize breeding support combining genetic analysis and medical care, intestinal flora testing, and product development and consulting using symbiotic bacteria. - FY2018RestatedAnnual report
「In particular, to eliminate genetic diseases, the company will provide breeding support that combines science, technology, and data, including genetic analysis, with medical support, while commercializing measures to prevent the onset of genetic diseases.」
The company continues to pursue a policy of providing breeding support that combines genetic analysis and medical care and commercializing measures to prevent the onset of genetic diseases. - FY2018-Q3RestatedAnnual report
「In particular, the company has advanced efforts to launch a genetic testing business aimed at eliminating genetic diseases. It is also pursuing breeding support aimed at achieving genetic-disease-free breeding, measures to prevent disease onset using symbiotic bacteria as a key, and research into various preventive measures to extend animals’ healthy life expectancy.」
The company continues its efforts to launch a genetic testing business, provide breeding support, and implement measures to prevent disease onset using symbiotic bacteria. - FY2018-Q2RestatedAnnual report
「In particular, the company has advanced efforts to launch a genetic testing business aimed at eliminating genetic diseases. It is also pursuing breeding support aimed at achieving genetic-disease-free breeding, measures to prevent disease onset using symbiotic bacteria as a key, and research into various preventive measures to extend animals’ healthy life expectancy.」
The company continues its efforts to launch a genetic testing business, provide breeding support, and implement measures to prevent disease onset using symbiotic bacteria. - FY2018-Q1AdvancedAnnual report
「In particular, the company has advanced efforts to launch a genetic testing business aimed at eliminating genetic diseases. It is also pursuing breeding support aimed at achieving genetic-disease-free breeding, measures to prevent disease onset using symbiotic bacteria as a key, and research into various preventive measures to extend animals’ healthy life expectancy.」
The company reported concrete progress in efforts to launch a genetic testing business, while continuing breeding support and research into preventing disease onset using symbiotic bacteria. - FY2017First statedAnnual report
「In particular, the company will step up efforts to eliminate genetic diseases by developing testing businesses, including analyses of disease-related genes, and providing breeding support aimed at achieving genetic-disease-free breeding.」
The company presented, for the first time as a standalone initiative, specific measures to advance the elimination of genetic diseases and achieve genetic-disease-free breeding through genetic analysis and other testing businesses and breeding support.